Halozyme (HALO) Loses 9% on Weak Earnings

We recently published 10 Losing Stocks in an Otherwise Optimistic Market. Halozyme Therapeutics Inc. (NASDAQ:HALO) was one of the worst performers on Wednesday. Halozyme snapped a two-day winning streak on Wednesday, shedding 9.01 percent to finish at $73.23 as investors digested a weak earnings performance in both the fourth quarter and full-year 2025. In an updated report, Halozyme Therapeutics Inc. (NASDAQ:HALO) said that net income last year fell by 28.6 percent to $317 million from $444 million in 2 ...